Navigation Links
Healthpoint Biotherapeutics Acquires Regranex® Gel
Date:6/2/2011

FORT WORTH, Texas, June 2, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that it has acquired Regranex® Gel, along with the corresponding intellectual property (including patents), from Systagenix. Terms of the deal were not disclosed.

"This acquisition is aligned with our strategic focus on building a portfolio of novel biopharmaceuticals for wound healing and tissue regeneration," said Travis E. Baugh, President and Chief Operating Officer of Healthpoint Biotherapeutics. "Moreover, Regranex® Gel is a good fit for our commercial organization, which has a well established record of successfully marketing biologics for wound care."

Regranex® Gel (0.01% Becaplermin) is a recombinant human platelet-derived growth factor (rhPDGF) and was the first biotechnology product approved for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond, and have adequate blood supply.  

About Regranex® Gel

Regranex® Gel (0.01% Becaplermin) is a recombinant human platelet-derived growth factor (rhPDGF) and was the first biotechnology product approved for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond, and have adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control. In clinical trials, Regranex® Gel in conjunction with good ulcer care demonstrated a statistically significant increase in the incidence of complete healing (defined as complete ulcer closure) versus placebo gel. It is not known if Regranex® Gelis effective for the treatment of pressure ulcers or ulcers that are due to poor blood flow (circulation). It is not known if Regranex® Gelis safe and effective in children under 16 years of age.

Important Safety Information<
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
2. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
3. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
4. Talecris Biotherapeutics Announces First Quarter 2011 Results
5. Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
6. Northwest Biotherapeutics Addresses Recent Market Activity
7. Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders
8. Talecris Biotherapeutics Announces Fourth Quarter and Full Year 2010 Results
9. Talecris Biotherapeutics Announces Teleconference and Webcast Information for Special Meeting of Shareholders
10. Talecris Biotherapeutics to Report Fourth Quarter and Full Year 2010 Financial Results
11. Talecris Biotherapeutics Announces Revised Record Date and Meeting Date for Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... British Columbia and MENLO ... --  DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar ... developing and commercializing proven cancer therapies in new ... at the 106th Annual Meeting of the ... Meeting on the potential for its lead product ...
(Date:4/20/2015)... 2015 Orthobiologics are substances that ... The orthobiologics market is a rewarding market, which represents ... global orthobiologics market report defines and segments the concerned ... orthobiologics market was valued at $5,712.4 million in 2014, ... at a CAGR of 6.7% from 2014 to 2019. ...
(Date:4/20/2015)... PointCross Life Sciences today announced a strategic ... Big Data and globally accessible environment for genomic interpretation ... of clinical trials and nonclinical studies. This platform will ... stratified patient selection and ex post analysis ... Highlighting the timing of this partnership, Dr. ...
(Date:4/20/2015)... -- "Everybody is affected by cancer sooner or later," Dr. ... We,ve got to get away from that."  If you,ve ... loved one or friend battling for their life against ... other treatments cause the human body. It,s almost enough ... succumb to the disease. Dr. Dionne has developed a ...
Breaking Biology Technology:DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2
... Leading medical malpractice insurance company, Healthcare Providers Insurance ... its New Jersey operations.  The company has opened a ... to continue servicing the medical community in New Jersey. ... in New Jersey since 2005.   ...
... AUSTIN, Texas, Aug. 1, 2011 Vermillion, Inc. (NASDAQ: ... the United States Patent and Trademark Office (USPTO) has issued ... Peripheral Artery Disease." The patent claims cover the biomarker alpha1beta ... diagnosis of PAD. "This will be our ...
... 1, 2011 International Isotopes Inc. (OTC Bulletin Board: ... under both ISO-9001 and ISO-13485 standards for the manufacture ... cobalt-60 products. "ISO" is the International Organization ... promulgates worldwide commercial quality standards for manufacture of a ...
Cached Biology Technology:Medical Malpractice Insurance Company- Healthcare Providers Insurance Exchange (HPIX) has Expanded its Presence in New Jersey, Opens New Office 2Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent 2Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent 3International Isotopes Inc. Announces Successful International Standards Certification for Manufacture of Its Nuclear Medicine Products and Devices 2International Isotopes Inc. Announces Successful International Standards Certification for Manufacture of Its Nuclear Medicine Products and Devices 3
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)...   NexID Biometrics LLC, whose spoof-mitigation technology ... announced the beginning of shipments of version 2.0 of ... company, based in Potsdam, N.Y. , ... which began here today at the Walter E. Washington ... its SDK boosts the accuracy rate range to 96.5 ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... tends to conjure up images of tropical vacations, complete ... Rapid climate change, and increased pollution, ocean acidification ... factors heavily stress corals, and thus put both the ... and shelter, and the $1 billion dollar tourism industry ...
... cell, little bubbles called vesicles serve as container ships, ... cell membrane. Some of these vesicles, called post-Golgi vesicles, ... Scientists have long believed that other, similar vesicles handle ... an independent process. By using a finely honed type ...
... Researchers studying the nervous control of nematode mating behavior ... to mate with a hermaphrodite. Writing in the open ... Paul Sternberg from the California Institute of Technology investigated ... tail muscles to achieve an exploratory embrace. ...
Cached Biology News:Cells use import machinery to export their goods as well 2Cells use import machinery to export their goods as well 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
... Provides a fast and easy method ... mitochondrial fraction from mammalian tissues. Most ... inner and outer membranes. The kit ... studies and proteome profiling. Also included ...
Sufficient reagents for 50 applications.Mitochondria Isolation Kit Reagent A, 50 ml Mitochondria Isolation Kit Reagent B, 500 l Mitochondria Isolation Kit Reagent C, 70 ml...
Biology Products: